India will have to abide by Australia's 14-day quarantine requirement ahead of the test series starting in December but arrangements will be made to ensure their players can prepare as well as possible, Cricket Australia (CA) said on Tuesday.
The Indian board's (BCCI) chief Sourav Ganguly told local media earlier this month he hoped Virat Kohli's side could have their quarantine "reduced a bit" before the first test in Brisbane from Dec. 3.
Australia requires international arrivals to isolate in quarantine hotels due to the COVID-19 pandemic, though some have been allowed to pass the period at home due to health reasons.
CA interim chief executive Nick Hockley suggested there was little prospect of India's players having a shorter quarantine.
"It’s widely known and unlikely international travel restriction will have lifted by the time India are due to come into the country," he told reporters on a video call.
"I think the two-week quarantine is pretty well defined. What we’re working on is making sure that within that quarantine environment, the players have got the absolutely the best training facilities so that their preparation for the matches is as optimal as it can possibly be."
Hockley said Australia was closely watching the West Indies tour of England, which has gone off largely without a hitch apart from fast bowler Joffra Archer breach of the team's biosecurity protocols.
The Adelaide Oval, which has an attached hotel, has been seen as a potential venue for India to train safely while in quarantine.
"Whether it's a hotel on-site or hotels in close proximity to venues, it’s about certainly creating that environment where we’re minimising the risk of infections," said Hockley.
"Creating a biosecure environment is the absolute priority because there’s just a huge amount at stake if we’re not able to do that."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.